Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 5/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.44 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LSS | P48449 | 1/20 | 0.42 |
| ▸ | PSD | A5PKW4 | 2/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5215641 | 0.90 | MAPK14 (0.71) | GCGRMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3561082 | 0.88 | MAPT (0.48) | KDM4ELMNAGAAALDH1A1MAPT | |
| SCHEMBL6516740 | 0.76 | GCGR (0.45) | GCGRMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL196861 | 0.76 | GCGR (0.67) | GCGRMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3558118 | 0.75 | GCGR (0.55) | GCGRMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4806075 | 0.75 | MAPK14 (0.46) | GCGRMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5214789 | 0.74 | GCGR (0.46) | GCGRMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3554322 | 0.73 | CNR1 (0.57) | GCGRMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3552541 | 0.73 | CNR1 (0.47) | GCGRMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3560568 | 0.73 | CNR1 (0.47) | GCGRMAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816357-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816357-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816357-B2 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1697371-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1697371-B1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20050171110-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171110-A1 | Azabicyclic heterocycles as cannabinoid receptor modulators | CNR1, CNR2, GPR18 | GCGR 559/4885MAPK14 2299/4885MAPK13 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.